| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H49BrN6O9S |
| Molecular Weight | 869.821 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(C[C@]1(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@@H](NC(=O)OC3CCCC3)C(C)(C)C)OC4=C5C=CC(OC)=C(Br)C5=NC(=C4)C6=CSC(NC(=O)C(C)C)=N6)C(O)=O)C=C
InChI
InChIKey=LLGDPTDZOVKFDU-XUHJSTDZSA-N
InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
| Molecular Formula | C40H49BrN6O9S |
| Molecular Weight | 869.821 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor developed by Boehringer-Ingelheim for the treatment of hepatitis C. Faldaprevir in combination with pegylated interferon and ribavirin, or interferon-free treatment with faldaprevir in combination with deleobuvir plus ribavirin provides high sustained virological response rates for HCV genotype 1 infection. The most common adverse events were gastrointestinal disorders, rash, and photosensitivity. The interferon-free combination of faldaprevir and deleobuvir with ribavirin was effective for HCV genotype 1 infection, although further improvements will still be needed. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.
Approval Year
PubMed
|
|
TARGET -> INHIBITOR |
|
||
|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 3 of 3 entries
